- Home
- ATHA vs FLUX Comparison
ATHA vs FLUX Comparison
Compare ATHA & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- FLUX
- Stock Information
- Founded
- ATHA 2011
- FLUX N/A
- Country
- ATHA United States
- FLUX United States
- Employees
- ATHA N/A
- FLUX N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- FLUX Industrial Machinery/Components
- Sector
- ATHA Health Care
- FLUX Miscellaneous
- Exchange
- ATHA Nasdaq
- FLUX Nasdaq
- Market Cap
- ATHA 21.0M
- FLUX 20.2M
- IPO Year
- ATHA 2020
- FLUX N/A
- Fundamental
- Price
- ATHA $0.26
- FLUX $1.83
- Analyst Decision
- ATHA Buy
- FLUX Strong Buy
- Analyst Count
- ATHA 4
- FLUX 3
- Target Price
- ATHA $11.25
- FLUX $6.33
- AVG Volume (30 Days)
- ATHA 214.5K
- FLUX 38.2K
- Earning Date
- ATHA 05-09-2025
- FLUX 05-08-2025
- Dividend Yield
- ATHA N/A
- FLUX N/A
- EPS Growth
- ATHA N/A
- FLUX N/A
- EPS
- ATHA N/A
- FLUX N/A
- Revenue
- ATHA N/A
- FLUX $63,074,000.00
- Revenue This Year
- ATHA N/A
- FLUX $11.85
- Revenue Next Year
- ATHA N/A
- FLUX $13.10
- P/E Ratio
- ATHA N/A
- FLUX N/A
- Revenue Growth
- ATHA N/A
- FLUX N/A
- 52 Week Low
- ATHA $0.22
- FLUX $1.15
- 52 Week High
- ATHA $3.67
- FLUX $4.98
- Technical
- Relative Strength Index (RSI)
- ATHA 45.40
- FLUX 54.30
- Support Level
- ATHA $0.23
- FLUX $1.77
- Resistance Level
- ATHA $0.30
- FLUX $2.13
- Average True Range (ATR)
- ATHA 0.03
- FLUX 0.17
- MACD
- ATHA 0.00
- FLUX 0.02
- Stochastic Oscillator
- ATHA 37.12
- FLUX 45.45
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.